We serve Chemical Name:4-(3,5-dichlorophenyl)benzaldehyde CAS:221018-04-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(3,5-dichlorophenyl)benzaldehyde
CAS.NO:221018-04-8
Synonyms:4pnl-q03-0;MFCD01862518
Molecular Formula:C13H8Cl2O
Molecular Weight:251.10800
HS Code:2913000090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:386.6ºC at 760 mmHg
Density:1.319g/cm3
Index of Refraction:1.626
PSA:17.07000
Exact Mass:249.99500
LogP:4.47290
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4pnl-q03-0 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD01862518 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD01862518 Use and application,MFCD01862518 technical grade,usp/ep/jp grade.
Related News: Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease. 4-(3,5-dichlorophenyl)benzaldehyde manufacturer The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). 4-(3,5-dichlorophenyl)benzaldehyde supplier The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). 4-(3,5-dichlorophenyl)benzaldehyde vendor The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body. 4-(3,5-dichlorophenyl)benzaldehyde factory The fine and functional chemicals sector provides new growth drivers.
